118th Congress · HOUSE BILLBILL

H.R. 198Drug Pricing Transparency and Accountability Act

To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.

Health
Introduced Jan 9, 2023
Last action Dec 17, 2024
Pipeline · Bill → Law
Step 1
Introduced
Jan 9, 2023
Step 2
Referred
Dec 17, 2024
E&C · Ways & Means
Step 3
Committee
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary

This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.

Provisions · 5 sectionsIntroduced in House
Timeline · 5 actions
Dec 17, 2024
Referred to the Subcommittee on Health.
Jan 20, 2023
Referred to the Subcommittee on Health.
Jan 9, 2023
Introduced in House
Jan 9, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 9, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.